Skip to main content
TipRanks
Go Ultimate75% OFF

NeuroOne Medical Technologies (NMTC) AI Stock Analysis

203 Followers
NMTC

NeuroOne Medical Technologies

(NASDAQ:NMTC)

Select Model
Rating:47Neutral
Price Target:$0.97â–²(36.69% Upside)
Action:reiterated
Date:10/05/26

The score is held down primarily by weak financial quality—very large operating losses and meaningful cash burn—despite strong revenue growth and low leverage. Technicals add additional pressure given the clear downtrend and negative momentum, even though the stock appears oversold. Positive corporate events (revenue strength, record purchase order, and product development progress) provide some offset, while valuation is difficult to assess due to a negative P/E and no dividend yield.

Positive Factors
Revenue GrowthSustained product revenue growth indicates increasing adoption of NeuroOne’s neurodiagnostic and neurosurgical devices. Continued expansion from approximately $3.5M in FY2024 to $10.5M in preliminary FY2026 suggests improving commercial traction and a broader revenue base.
Negative Factors
Severe Operating LossesVery negative operating and net margins show that current revenue scale is not yet sufficient to cover the company’s cost base. Unless gross profit expands faster than operating expenses, revenue growth may continue without translating into sustainable earnings or internally funded expansion.

NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%NMTC-81.50%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.43M
Dividend Yield
―
Average Volume (3M)
336.58K
Price to Earnings (P/E)
-0.8
Beta (1Y)
1.47
Revenue Growth
-1.67%
EPS Growth
7.34%
Country
US
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

NeuroOne Medical Technologies Business Overview & Revenue Model

Company Description

NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neur...

How the Company Makes Money

NeuroOne makes money primarily by selling its neurostimulation and neurodiagnostic device products (notably thin-film electrode arrays and associated components) to healthcare providers and/or through distribution partners. Revenue is generated on a...

NeuroOne Medical Technologies Earnings Call Summary

Earnings Call Date:Aug 19, 2026(Q3-2026)|% Change Since:-62.45%|Next Earnings Date:Dec 16, 2026
Earnings Call SentimentNeutral

The call delivered strong operational and clinical progress — including double-digit revenue growth (+16% YoY), 43% growth in orders, improved gross margins (+6.0 percentage points), ISO 13485 certification, and meaningful advances across product lines (OneRF, Trigeminal, StereoCED, BVNA). However, these positives are balanced by material near-term challenges: manufacturing lead times and backlog that constrain revenue recognition, rising operating expenses and widening net loss, and a significant decline in cash and working capital that creates liquidity pressure. Management has mitigation plans (second manufacturing site, ATM raises, supply acceleration) and clear clinical/regulatory milestones, but the financial and execution risks temper the upside from operational wins.

Positive Updates

Product Revenue Growth
Product revenue for OneRF grew 16% year-over-year to $2.0M in Q3 FY2026 (from $1.7M in Q3 FY2025).

Negative Updates

Manufacturing Delays and Backlog Risk
Supplier lead times of up to ~6 months and manufacturing capacity constraints created a backlog ($1.7M as of June 30, 2026), limiting the company's ability to fully convert $11.2M in orders into recognized revenue this fiscal year; management expects to address backlog by end of calendar Q4 2026 and bring a second, larger manufacturing site online in early 2027.

Company Guidance

Guidance for fiscal 2026 reiterated expected aggregate product orders of approximately $11.2 million and recognized revenue of $9.2–$10.5 million (timing-dependent); Q3 product revenue was $2.0M (up 16% YoY from $1.7M) with $2.7M of orders in the quarter (up 43% YoY) and a $1.7M backlog as of June 30, 2026 that management expects to address by the end of calendar Q4 2026 through supplier acceleration and qualification of a second, larger manufacturing site expected in early 2027. Gross margin expanded to 59.9% (product gross profit $1.2M vs 53.9% a year ago), total operating expenses were $3.6M (R&D $1.4M; SG&A $2.2M), net loss was $2.0M ($0.23 basic / $0.28 diluted) versus $1.5M ($0.19 / $0.22) prior-year, cash and cash equivalents were $2.0M (vs $6.6M on 9/30/25) with $1.1M AR expected to convert in Q4, working capital $3.7M (vs $7.9M), no debt, and $1.4M raised via ATM in 2026 ($0.4M in Q3; $1.0M on July 13 via 400,346 shares); strategic milestones/timing include ISO 13485 certification enabling international expansion, StereoCED aimed for investigational human studies by end-September 2026, and a BVNA 510(k) submission targeted in H2 2027, while a lead investor increased ownership from 7.4% to 12.5%.

NeuroOne Medical Technologies Financial Statement Overview

Summary

Revenue is ramping quickly into TTM (~$10.0M) with improving gross margin versus earlier years, but operating performance remains severely negative (EBIT margin ~-80%, net margin ~-72%). Cash flow is a major weakness with substantial and worsening burn (TTM operating cash flow ~-$7.1M; FCF ~-$7.2M). The balance sheet helps somewhat due to minimal debt (~$0.07M; debt-to-equity ~0.02), but equity has fallen meaningfully (FY2025 ~$7.1M to TTM ~$3.8M), reflecting ongoing losses.

Income Statement

27Negative

Balance Sheet

58Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue10.00M12.10M3.45M1.95M171.17K178.15K
Gross Profit5.57M8.14M1.08M456.52K-70.79K-97.75K
EBITDA-6.91M-3.01M-11.84M-11.66M-9.88M-9.86M
Net Income-7.15M-3.61M-12.32M-11.86M-10.00M-9.95M
Balance Sheet
Total Assets6.19M10.79M5.37M8.10M12.82M7.94M
Cash, Cash Equivalents and Short-Term Investments2.05M6.57M1.46M5.32M11.14M6.90M
Total Debt73.32K266.81K260.16K184.40K202.90K315.67K
Total Liabilities2.42M3.71M4.55M1.85M3.22M1.38M
Stockholders Equity3.77M7.07M822.01K6.25M9.60M6.55M
Cash Flow
Free Cash Flow-7.16M-2.92M-11.13M-13.27M-7.79M-8.67M
Operating Cash Flow-7.05M-2.84M-11.01M-12.89M-7.52M-8.60M
Investing Cash Flow-109.54K-81.74K-120.20K2.65M-3.24M-67.08K
Financing Cash Flow1.17M8.33M7.27M7.40M12.02M11.53M

NeuroOne Medical Technologies Technical Analysis

Technical Analysis SentimentNegative
Last Price0.71

Price Trends

50DMA1.08Negative
100DMA1.59Negative
200DMA2.93Negative

Market Momentum

MACD-0.10Positive
RSI30.72Neutral
STOCH-0.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 1.08, and below the 200-day MA of 2.93, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 30.72 is Neutral, neither overbought nor oversold. The STOCH value of -0.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.

NeuroOne Medical Technologies Risk Analysis

NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We may not be successful in commercializing our technology.Q3, 2024
2.An inability to obtain a supply of components and raw material products could have a material adverse effect on our business, financial condition and results of operations.Q3, 2024
3.We may be adversely affected by the effects of inflation.Q3, 2024

NeuroOne Medical Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NMTC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NMTCNMTC47Neutral$6.43M-0.77-126.45%―-1.67%7.34%
SRTSSRTS45Neutral$37.20M-2.31-38.65%―-53.33%-429.93%
ECORECOR42Neutral$44.19M-3.31498.83%―27.26%20.47%
RBOTRBOT40Underperform$2,2820.00-333.19%――36.00%

* Healthcare Sector Average

Performance Comparison

-100%0%100%NMTCSRTSECORMODDRBOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NMTC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NMTCNeuroone Medical Technologies Corporation0.71-2.90-80.42%
SRTSSensus Healthcare, Inc.2.26-1.67-42.49%
ECORElectrocore4.790.204.36%
MODDModular Medical Inc.1.80-11.61-86.58%
RBOTVicarious Surgical Inc.0.02-2.56-99.22%

NeuroOne Medical Technologies Corporate Events

Business Operations and StrategyFinancial Disclosures

NeuroOne Reports Strong Fiscal 2026 Revenue Growth

Positive
Oct 5, 2026

On October 5, 2026, NeuroOne reported preliminary, unaudited fiscal 2026 product revenue of approximately $10.5 million, a 15.6% increase year over year and at the top of its guidance range. The company also disclosed preliminary fourth-quarter produ...

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements

NeuroOne Advances StereoCED Toward Human Clinical Studies

Positive
Aug 27, 2026

On August 27, 2026, NeuroOne reported the successful completion of three large-animal procedures at the University of Minnesota using its next-generation StereoCED platform for robotic-assisted intracerebral drug delivery and electrophysiological mon...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026